Zivo Bioscience, Inc. (ZIVOW) intrinsic value & 10-year financials
Zivo Bioscience, Inc. (ZIVOW) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 67.4% a year to $157.2K, with an average return on invested capital of 196.8%.
- Graham intrinsic value
- —
- Revenue (FY2024)
- $157.2K
- Revenue growth (10-yr CAGR)
- 67.4%
- ROIC (10-yr avg)
- 196.8%
- Free cash flow (FY2024)
- —
ZIVOW 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | $157.2K | -$13.4M | -$4.23 | — | -8498.9% | 605.5% |
| FY2023 | $27.6K | -$7.8M | -$4.60 | — | -26267.7% | 371.7% |
| FY2022 | $0 | -$8.7M | — | — | — | 383.3% |
| FY2021 | $0 | -$9.2M | — | — | — | 128.2% |
| FY2020 | $20.0K | -$9.1M | — | — | -42778.4% | 90.5% |
| FY2019 | $0 | -$11.5M | — | — | — | 132.5% |
| FY2018 | $0 | -$14.6M | — | — | — | 75.9% |
| FY2017 | $0 | -$10.0M | — | — | — | 67.1% |
| FY2016 | $0 | -$6.1M | — | — | — | 52.4% |
| FY2015 | $0 | -$5.8M | — | — | — | 61.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Zivo Bioscience, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Zivo Bioscience, Inc. has earned high returns on invested capital, averaging 62.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Zivo Bioscience, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Zivo Bioscience, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-140.50 per share.